<DOC>
	<DOCNO>NCT00006213</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Phase I trial study effectiveness BMS-214662 treating patient acute leukemia , myelodysplastic syndrome , chronic myeloid leukemia blast phase</brief_summary>
	<brief_title>BMS-214662 Treating Patients With Acute Leukemia , Myelodysplastic Syndrome , Chronic Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity BMS-214662 patient acute leukemia , myelodysplastic syndrome , chronic myeloid leukemia blast phase . II . Determine preliminary evidence antileukemia activity drug patient . OUTLINE : This dose escalation study . Patients receive BMS-214662 IV 1 hour weekly 4 week . Treatment continue every 4 week maximum 12 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos BMS-214662 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A maximum 30 patient accrue study within 10 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Patients must : AML , ALL , highrisk MDS ( RAEB RAEBt ) : Not respond ( CR ) initial induction chemotherapy , Recurred initial CR &lt; 1 year , Recurred initial CR &gt; 1 year fail respond initial reinduction attempt , Recurred , Chronic myeloid leukemia myeloid blast phase Patients CML blast phase may receive BMS214662 first therapy blast phase fail treatment blast phase Patients refractory relapse acute promyelocytic leukemia eligible provide fail ATRAcontaining regimen Performance status = &lt; 02 Signed inform consent indicate patient aware investigational nature study keep policy hospital Patients must chemotherapy 4 week prior enter study recover toxic effect therapy ; patient evidence rapidly progressive disease ( i.e. , absolute peripheral blood blast count &gt; = 5 x 10^9/L increase &gt; = 1 x 10^9/L/24 hour ) may receive treatment 4 week previous treatment provide recover toxic effect therapy ; use hydroxyurea patient rapidly proliferative disease allow 24 hour prior start therapy Bilirubin = &lt; 1.5 mg/dL Creatinine = &lt; 1.5 mg/dL creatinine clearance &gt; = 60 mL/hr Patients likely benefit allogeneic bone marrow transplantation ( i.e. , age &lt; 60 year physiological age histocompatible donor ) exclude study unless therapy feasible Pregnant nursing female exclude ; patient childbearing potential practice effective method contraception Patients prolong QTc interval EKG exclude</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>